SS Innovations International Inc. develops and commercializes surgical robotic technologies centered on the SSi Mantra Surgical Robotic System, a modular multi-arm platform used across multiple surgical specialties. Company news commonly covers SSi Mantra procedure milestones, global system installations, telesurgery demonstrations, regulatory approvals in international markets, and financial results tied to installations, procedures and revenue.
Updates also address the company’s surgical robotics ecosystem, including the SSi MantrAsana tele-surgeon console, the MantraM mobile robotic telesurgery unit, SSi Mudra instrumentation, and development-stage concepts such as SSi Vimana Aero, SSi Avtara and SSi Operion. Capital actions, Nasdaq trading status and company-hosted robotic surgery conferences are additional recurring themes.
SS Innovations International (SSII) has received approval to uplist from OTC to Nasdaq Capital Market, with trading set to commence on April 25, 2025, under the same ticker 'SSII'. The company, focused on affordable surgical robotic technologies, reported significant achievements with its SSi Mantra surgical robotic system:
Key highlights include:
- Installation of 80 systems across 75 hospitals in India and other countries
- 3,500+ successful surgeries, including 195+ cardiac procedures with zero device-related complications
- First Indian company to receive CDSCO approval for telesurgery
- Completed 16 telesurgeries, including world's first robotic cardiac telesurgeries at distances up to 1,200 miles
The company reported strong financial performance with revenue of $20.6 million for 2024, a 251% increase from 2023's $5.9 million, and improved gross margin from 12.3% to 40.9%. SSII is pursuing EU CE Mark and U.S. FDA approval, expected in late 2025 and early 2026, respectively.
SS Innovations International (SSII) has reported significant achievements in 2024, with its SSi Mantra surgical robotic system completing over 3,500 surgeries across 80 installations in 75 hospitals. The company sold 37 systems and installed 8 more on a Pay-Per-Use Lease model in 2024.
Preliminary unaudited results show expected 2024 revenues of over US$22 million, representing a nearly four-fold increase from 2023. Gross margins improved from 12.30% to 36.90%. For Q1 2025, SSII anticipates reaching 78 installations with estimated revenues of US$6.4 million and 45% gross margin.
Key achievements include: zero device-related complications across all procedures, successful telesurgery implementation with 16 procedures completed, expansion of manufacturing capacity to 20 units monthly, training of over 750 surgeons, and regulatory approvals in multiple countries. The company expects FDA and CE approvals by late 2025 or early 2026.
SS Innovations International (OTC: SSII) has secured regulatory approvals for its SSi Mantra 3 Surgical Robotic System in both the Philippines and Ukraine. The company partnered with RBGM Medical Express Sales Inc. in Manila and Loran Group in Kiev for distribution.
The Philippines market, with nearly 4,000 hospitals, represents a significant opportunity for expanding robotic surgery access. In Ukraine, despite ongoing conflict and damaged medical facilities, the Certificate of Conformity approval positions SSII to participate in the country's medical infrastructure rebuilding efforts.
The SSi Mantra 3 system features 3-5 robotic arms, 3D 4K monitoring, and over 40 different types of robotic endo-surgical instruments. It has been clinically validated in India across 80+ surgical procedures. The company anticipates receiving FDA and CE Mark approvals in the second half of 2025.
SS Innovations International (OTC: SSII) has achieved a significant milestone by successfully performing India's first North-to-South robotic cardiac telesurgery using its SSi Mantra 3 Surgical Robotic System. The procedure connected the company's headquarters in Gurugram to Aster CMI Hospital in Bengaluru, spanning over 2,000 kilometers.
The 2-hour-40-minute surgery involved closing a complex Atrial Septal Defect in a 35-year-old patient. Led by Dr. Sudhir Srivastava from Gurugram and supported by Dr. Arul Furtado's team in Bengaluru, the procedure demonstrated exceptional precision with minimal latency.
The SSi Mantra 3, India's first CDSCO-approved surgical robotic system for telesurgery, represents a significant advancement in making specialized surgical care accessible across long distances. This achievement follows previous successful telesurgeries spanning 40 km and 286 km, marking a substantial leap in remote surgical capabilities.
SS Innovations International (OTC: SSII) unveiled its groundbreaking SSI Mantra Tele-Sync Mobile Unit (SSI MantraM) at the Second Global Multi-Specialty Robotic Surgery Conference in Gurugram, India. This first-of-its-kind mobile tele-surgical unit integrates the SSi Mantra 3 Surgical Robotic System with high-speed connectivity to enable remote surgical procedures.
The conference attracted over 1,200 medical professionals. The SSI MantraM is designed to provide robotic-assisted surgery to underserved communities through telesurgery capabilities and real-time collaboration between remote and on-site surgical teams. Notably, the SSi Mantra 3 system is the only robotic system globally to receive CDSCO regulatory approval for telesurgery and tele-proctoring.
The system features 3-5 robotic arms, 3D 4K monitoring, and supports over 40 different types of robotic endo-surgical instruments across various specialties. The company anticipates receiving FDA and CE Mark approval in the second half of 2025.
SS Innovations International (OTC: SSII) announced its 2nd Global Multi-Specialty Robotic Surgery Conference (SMRSC 2025) to be held in Gurugram, India, from March 7-9, 2025. The conference will showcase the company's SSi Mantra 3 Robotic Surgical System, which has already facilitated over 3,200 surgeries across 70+ hospitals globally.
The event will feature live robotic surgeries in multiple specialties and the launch of the SSi Mantra Mobile Unit, a surgical bus designed to expand access to robotic surgical care in underserved areas. The SSi Mantra 3 is notably the only robotic system worldwide with regulatory approval for telesurgery and tele-proctoring from CDSCO, enabling remote surgeries and medical education.
The system features 3-5 robotic arms, 3D 4K monitoring, and over 40 different types of robotic endo-surgical instruments. The company anticipates receiving FDA and CE Mark approvals in the second half of 2025.
SS Innovations International (OTC: SSII) has achieved a historic milestone in global healthcare by successfully performing the world's first robotic cardiac telesurgeries using its SSi Mantra 3 Surgical Robotic System. The procedures, including a robotic-assisted Internal Mammary Artery Harvesting and a Robotic Beating Heart Totally Endoscopic Coronary Artery Bypass (TECAB), were conducted remotely between Gurugram and Jaipur, India, spanning 286 kilometers with a latency of only 40 milliseconds.
This breakthrough was made possible due to the recent approval from the Central Drugs Standard Control Organization (CDSCO), India's regulatory authority, making SS Innovations the first in India to receive such approval for telesurgery and teleproctoring capabilities. The SSi Mantra 3 system has been clinically validated in over 80 different types of surgical procedures in India and is awaiting FDA and CE Mark approvals by the second half of 2025.
The success of these telesurgeries underscores the potential of advanced surgical technology in overcoming geographical barriers, enabling timely and precise medical care. It also marks a significant step forward in making high-quality healthcare accessible to underserved communities, particularly in rural areas.
SS Innovations International (SSII) announced the completion of BDO India LLP's re-audit of its 2022-2023 financial statements, following the termination of its previous auditor BF Borgers CPA PC. The re-audit revealed material errors in prior statements, leading to restated financials showing improved metrics: shareholders' equity increased by $5.42 Million to $19.72 Million, and working capital surplus rose by $3.85 Million to $12.96 Million.
The company has withdrawn its Form S-1 Registration Statement and plans to uplist to NASDAQ without completing the previously contemplated offering. SSII reports over 2,500 completed robotic surgical procedures using its SSi Mantra Surgical Robotic System, with systems now installed in 5 countries, including recent expansion to Indonesia where it completed the country's first robotic cardiac surgery.
SS Innovations International (OTC: SSII) has achieved a significant milestone by becoming the first company in India to receive CDSCO regulatory approval for Telesurgery and Teleproctoring capabilities of its SSi Mantra surgical robotic system. This breakthrough enables remote surgical procedures and training, particularly benefiting patients in rural areas with access to specialized medical care.
The SSi Mantra system features advanced capabilities including 3-5 robotic arms, a 3D 4K monitor, and over 40 different types of robotic endo-surgical instruments. The system has been clinically validated in India across more than 80 different surgical procedures. The company is currently seeking FDA and CE Mark approvals, anticipated in the second half of 2025.
SS Innovations International (OTC: SSII) has achieved a significant milestone by completing Indonesia's first robotic cardiac surgery using its SSi Mantra Surgical Robotic System at Harapan Kita National Cardiac Hospital in Jakarta. Dr. Sudhir Srivastava, the company's Founder and CEO, performed the first Beating Heart Totally Endoscopic Coronary Artery Bypass (TECAB), followed by 7-8 additional robotic-assisted procedures. The procedures included bilateral IMA CABG, ASD Repair, and TECAB surgeries. This achievement marks a significant advancement for Indonesia's healthcare sector, with its population of over 284 million and nearly 3,000 hospitals.